Celgene distributes a letter for Innohep

Celgene has issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep injection (tinzaparin sodium) may increase the risk for death, compared to unfractionated heparin (UFH) when used to treat elderly patients with renal insufficiency. The company recommends considering alternatives to Innohep when treating these patients.

Innohep is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium.

For more information call (866) 742-7646 or visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm090743.htm.